Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.
Thanks!

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

Denmark's pilot pharma trial learns from Canada's lesson

Europe is open for business, and Denmark wants to be the first-mover. Europe, forecasted to be the world’s biggest legal cannabis market by 2024 will exceed North America, the dominant market today, according to Prohibition Partners. Denmark is already leading the way in Europe by launching a Big Pharma model as the efficacy of cannabis as a medicine gains ground through testing and clinical trials, eliminating patients’ reliance on opiates and other pharmaceutical drugs. Denmark’s Big Pharma model stems from its expertise in horticulture and pharma, and low support for recreational cannabis, propelling it into the future before any other nation in the EU.

In 2018, Denmark launched its first 4-year medical marijuana program to improve access to patients in need of cannabis, initially for those suffering from multiple sclerosis and nausea after chemotherapy, and later including paraplegics and pain patients. “Ever since expanding the patient groups, we were not able to import enough cannabis,” stated Jane Heitmann, Danish Liberal party MP. “We gave the option to foreign companies to cultivate in Denmark.”

Read more at cannabislaw.report

Publication date: